[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605256":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":24,"locations":34,"responsibleParty":51,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":66,"studyType":67,"phases":10,"briefSummary":57,"conditions":68,"keywords":72,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University Hospital Pilsen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1",null,"Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.",[13,14],"Diagnostic Test: Neurocognitive assessment","Diagnostic Test: Urine toxicological assessment",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"DIAGNOSTIC_TEST","Neurocognitive assessment","Neurocognitive battery:\n\nTMT-Trail Making Test Auditory Verbal Learning Test Stroop Test Tower of London (ToL), Shallice version Continuous Performance Test-Identical Pairs\n\nOther psychometrics:\n\nThe level of dependence is quantified using the CAST (Cannabis Abuse Screening Test)",[9],{"type":17,"name":22,"description":22,"armGroupLabels":23,"otherNames":10},"Urine toxicological assessment",[9],[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Jiri Podlipny, MD, Ph.D.","CONTACT","+420 377 103 209","podlipny@fnplzen.cz",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"Frantisek Nekvapil, MD","+420 377 103 101","nekvapilfr@fnplzen.cz",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":38,"countryCode":10,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Pilsen","Czechia","30100",{"type":41,"coordinates":42},"Point",[43,44],13.37759,49.74747,{"lat":44,"lon":43},[47,48,49],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},{"name":26,"role":50,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100605256","cannabis-abstinence-and-neurocognitive-assessment-in-adolescence-100605256",false,"NCT07160153","Cannabis Abstinence and Neurocognitive Assessment in Adolescence","CANAA","Inclusion Criteria:\n\n* Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.\n\nExclusion Criteria:\n\n* psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.\n* somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.\n* Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.","ALL","15 Years","18 Years",{"count":64,"type":65},29,"ESTIMATED","2 Months","OBSERVATIONAL",[69,70,71],"Cannabis Dependence","Harmful Use","Cognitive Assessment",[69,73,74,75,76],"Cannabis Use Disorder","Abstinence","Cognitive Function","Disorder; Abstinence; Cognitive Function; Neuropsychological","2025-09-15",{"date":79,"type":80},"2025-09-19","ACTUAL",{"date":82,"type":80},"2024-12-03",{"date":84,"type":65},"2029-08-31",{"name":5,"class":6},1]